Analyzing data from the Johannesburg Cancer Case Control Study, researchers from the Cancer Epidemiology Research Group in Johannesburg, South Africa concluded that use of oral or injectable hormone contraceptives is associated with a very small-- and temporary-- increased risk of developing breast or cervical cancer compared to women who don't use these products.
Within ten years of stopping the use of these injectable contraceptives, the cancer risk returns to the same risk that they had before they began taking them.
The use of injectable contraceptives is high in South Africa compared to other parts of the world.
Researchers also determined that, for women on a hormonal contraceptive for five years or more, the risks of developing ovarian cancer and endometrial cancer are significantly reduced.
Publishing in PLoS Medicine, they concluded, "The evidence from this study, in the context of the evidence to date, indicates that the adverse events of both oral and injectable hormonal contraceptives on breast and cervical cancer are transient, and risks in users return to those of never users within 10 years after stopping use."
Source: MedPage Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
